Caribou Biosciences (CRBU) Liabilities and Shareholders Equity (2020 - 2026)

Caribou Biosciences (CRBU) has 7 years of Liabilities and Shareholders Equity data on file, last reported at $149.0 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 45.55% year-over-year to $149.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $740.3 million (down 43.24% YoY) and the FY2025 annual result came in at $175.4 million, down 44.03% from the prior year.
• Liabilities and Shareholders Equity fell to $149.0 million in Q1 2026 per CRBU's latest filing, from $175.4 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $457.5 million in Q3 2023 and bottomed at $149.0 million in Q1 2026.
• The 5-year median for Liabilities and Shareholders Equity is $349.6 million (2023), against an average of $334.0 million.
• The widest annual swing landed in 2022, when Liabilities and Shareholders Equity surged 166.02%; it then plunged 45.55% in 2026.
• Tracing CRBU's Liabilities and Shareholders Equity over 5 years: stood at $373.8 million in 2022, then gained by 15.64% to $432.2 million in 2023, then decreased by 27.51% to $313.3 million in 2024, then sank by 44.03% to $175.4 million in 2025, then declined by 15.04% to $149.0 million in 2026.
• Per Business Quant, the three latest CRBU Liabilities and Shareholders Equity figures stand at $149.0 million (Q1 2026), $175.4 million (Q4 2025), and $195.0 million (Q3 2025).

Peer Comparison